Straits Times Index
3,324.19 +10.05 (+0.30%) Nikkei
39,173.15 +368.50 (+0.95%) Hang Seng
18,013.43 -14.28 (-0.08%) FTSE 100
8,281.55 +43.83 (+0.53%) Bitcoin USD
61,114.45 -1,212.76 (-1.95%) CMC Crypto 200
1,267.87 +18.75 (+1.50%)
SLNO Sep 2024 45.000 call
| Previous close | 8.15 |
| Open | 8.15 |
| Bid | 5.00 |
| Ask | 9.50 |
| Strike | 45.00 |
| Expiry date | 2024-09-20 |
| Day's range | 8.15 - 8.15 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
GlobeNewswireSoleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to eight new employees. The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 247,200 shares of common stock to eight employ
- GlobeNewswire
Soleno Therapeutics Set to Join Russell 3000® Index
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24
- GlobeNewswire
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4,
